Healthcare Global Enterprises Limited has released the transcript of its earnings call, providing investors access to management’s commentary on the company’s financial performance for the first quarter of FY27. The audio recording of the discussion with analysts and investors is now available on the company’s investor relations website, following the earlier intimation dated July 27, 2026.

The earnings call was conducted on August 07, 2026, to review the unaudited financial results for the quarter ended June 30, 2026. The discussion covered both standalone and consolidated figures, offering insights into the operational and financial health of the healthcare services provider during the period.

Regulatory Compliance

The disclosure was made in accordance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was submitted to the Compliance Departments of both the National Stock Exchange of India Limited and BSE Limited, ensuring timely dissemination of material information to the market.

Accessing the Earnings Call

Investors and analysts can access the full audio recording of the earnings call via the company’s official website. The link directs users to the investor relations section, where the recording is hosted for public viewing. This transparency measure allows stakeholders to hear directly from management regarding the quarterly performance and strategic outlook.

What the Numbers Show

While the specific financial metrics such as net profit, revenue, or EBITDA are not detailed in this particular filing, the release of the earnings call transcript signifies the completion of the quarterly reporting cycle for Q1FY27. The availability of the recording enables detailed analysis of management’s narrative surrounding the financial results, which may include commentary on patient volumes, margin trends, and capital expenditure plans that are not captured in the raw numbers alone.

Healthcare Global Enterprises delivered a robust start to FY27, reporting consolidated revenue of ₹6,951 million in Q1FY27, a 13% year-on-year increase driven by an 11% surge in patient volumes. The company’s adjusted EBITDA grew 20% to ₹1,339 million, expanding margins to 19.4% from 18.2% in Q1FY26, while profit after tax (PAT) surged 190% to ₹138 million. This performance highlights the strength of its integrated oncology model and the successful ramp-up of new capacity, particularly the North Bengaluru facility which commenced operations in May 2026.

The Board of Directors approved the unaudited financial results on August 06, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results reflect broad-based growth across its South, West, and East clusters, supported by an improved payor mix where non-institutional revenue grew 17% YoY, increasing its contribution from 67% to 69%. Notably, the company divested its fertility business in June 2026, which contributed ₹169 million in revenue and ₹23 million in EBITDA during the quarter.

Financial Performance Highlights

Revenue growth was primarily volume-led, with average revenue per patient (ARPP) increasing by 2% to ₹85,943. Reported EBITDA stood at ₹1,223 million, impacted by startup losses of ₹70 million from the new North Bengaluru center and an EPCG-related provision of ₹46 million. Excluding these one-time items, adjusted EBITDA margins improved by 120 basis points year-on-year. International business revenue also grew 9% YoY to ₹208 million, driven by stronger inflows for radiation oncology and PET cases.

Regional Growth Dynamics

The West cluster remained the largest revenue contributor at 43% (₹3,010 million), growing 9% YoY on strong patient inflows in Maharashtra, though growth was moderated in Gujarat due to case-mix shifts toward medical oncology. The South cluster delivered 16% YoY growth to ₹2,765 million, led by the Bengaluru Center of Excellence and the new North Bengaluru facility. The East cluster showed the highest growth rate at 22% YoY to ₹799 million, driven by a 25% surge in patient volumes, although ARPP declined slightly due to higher participation from state government schemes.

Strategic Expansion and Capacity Additions

Healthcare Global Enterprises added 121 operational beds in Q1FY27, bringing total operational beds to 2,855. Key additions included 56 beds at North Bengaluru, 26 at Ranchi, and smaller increments across Borivali, Nashik, Hubli, and Kenya. The company commissioned an MR-LINAC at North Bengaluru in July 2026, enhancing its adaptive radiation therapy capabilities. Additionally, Rajkot was upgraded to a Comprehensive Cancer Care Centre with a new LINAC, and robotic surgery capabilities were strengthened at Nashik and Bengaluru.

What the Numbers Show

The divergence between reported and adjusted EBITDA highlights the transitional costs associated with aggressive capacity expansion. While startup losses at North Bengaluru pressured reported margins, the underlying operational efficiency is evident in the 20% growth in adjusted EBITDA versus only 13% revenue growth. This suggests successful operating leverage as fixed costs are spread over a larger patient base. Furthermore, the shift in payor mix towards cash and TPA (now 66% combined vs 63% in FY25) supports the margin expansion narrative, indicating a strategic move away from lower-margin government schemes in key markets.